Velarion Records
Free. Unsubscribe any time.

Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals, Inc. filed 14 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 4 reporting owners, covering 16 transactions and 340,095 shares. 3 carry the SEC's AFF10B5ONE flag; 11 name a plan only in a footnote. 2 results prints are on file in the same window.

What stands out

Trades in Apellis Pharmaceuticals, Inc. 16

Adoption dates in Apellis Pharmaceuticals, Inc. 1

Results prints in Apellis Pharmaceuticals, Inc. 2

Trades before a print in Apellis Pharmaceuticals, Inc. 0

Interval to Apellis Pharmaceuticals, Inc.’s next reported results date

How the interval and sources are counted →

Adoption dates Apellis Pharmaceuticals, Inc. states

Filing text: “10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025”

Reported results dates on file

A proxy statement is on file for this company in the same window (2025-04-23), which is where a company states its own trading policy.

Other companies with plan records

Sources: SEC EDGAR full-text search and the SEC submissions API.

The address of this record

Apellis Pharmaceuticals, Inc.’s insider trading plan record — 14 Form 4 statements in the 2025 filing year — is published at one address, this page. When you cite or link the record, use https://velarionrecords.com/plan10b5/issuer/0001492422.